Greelish James P, Ailiwadi Maneesh, Balaguer Jorge M, Ahmad Rashid M, Zhao David X, Petracek Michael R, Byrne John G
Department of Cardiac Surgery, Vanderbilt University Medical Center, Nashville, Tennessee 37232-8815, USA.
Curr Opin Cardiol. 2006 Mar;21(2):113-7. doi: 10.1097/01.hco.0000210307.87231.34.
This article reviews unique advantages emerging in valvular heart disease as the technology of invasive cardiology and cardiac surgery begin to merge.
Minimally invasive valve surgery is increasing in popularity and has helped to reduce morbidity. In addition, preoperative or intraoperative treatment of coronary artery disease by a percutaneous approach has simplified operations and allowed more liberal use of non-traditional incisions.
Percutaneous intervention with drug-eluting stents has provided early evidence for decreased restenosis and improved long-term patency rates. At the same time, cardiac surgery has moved toward less invasive approaches performed in new imaging arenas known as 'hybrid' operating rooms. Combining these technological advances is providing unique solutions to valvular heart disease also requiring revascularization, and will likely become the next horizon for strategies in cardiovascular medicine.
随着侵入性心脏病学技术与心脏外科手术开始融合，本文回顾了瓣膜性心脏病中出现的独特优势。
微创瓣膜手术越来越受欢迎，并有助于降低发病率。此外，通过经皮途径对冠状动脉疾病进行术前或术中治疗简化了手术，并允许更广泛地使用非传统切口。
药物洗脱支架的经皮介入已为降低再狭窄和提高长期通畅率提供了早期证据。与此同时，心脏外科手术已朝着在称为“杂交”手术室的新成像环境中进行的侵入性较小的方法发展。将这些技术进步相结合，为也需要血运重建的瓣膜性心脏病提供了独特的解决方案，并可能成为心血管医学策略的下一个发展方向。
